Journal
HAEMATOLOGICA
Volume 93, Issue 6, Pages 921-924Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.12165
Keywords
WT1; minimal residual disease; acute leukemia; RQ-PCR
Categories
Funding
- AIRC (Associazione Italiana per la Ricerca sul Cancro)
- CNR (Progetto Finalizzato Oncologia)
- MURST-COFIN 2003
- AIL (Associazione Italiana contro le Leucemie)
- CRT
- Regione Piemonte
Ask authors/readers for more resources
The Wilms' tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients. The study was designed to demonstrate the potential use of WT1 to establish quality of remission in acute leukemia patients for early identification of patients at high risk of relapse. A prospective study based on a quantitative Real-Time PCR (TagMan) assay in 562 peripheral blood samples collected from 82 acute leukemia patients at diagnosis and during follow-up was established.The evaluation of WT1 in peripheral blood samples after induction chemotherapy can distinguish the continuous complete remission patients from those who obtain only an apparent complete remission and who could relapse within a few months. WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available